Evolus Q2 revenue $84.1M (+21% YoY); raises FY2026 guidance; adds Profhilo U.S. rights

Evolus, Inc.

Q2 net revenue $84.1M (+21% YoY); GAAP operating loss $4.5M; adjusted EBITDA $4.7M (vs -$7.9M prior year).
Raises FY2026 revenue guidance to $330-337M; raises adjusted gross margin to 67.0-67.5%; narrows non-GAAP opex to $212-216M.
Exclusive U.S. partnership for Profhilo (IBSA); peak revenue >$100M; U.S. launch expected 2030.
Expands Estyme HA gel franchise into Canada, Australia, New Zealand; commercialization expected 2028.
Cash $45.2M; $120M non-dilutive capacity; reaffirms 2028 outlook ($450-500M revenue, 13-15% adj EBITDA margin).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.